We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

68 hedge funds and large institutions have $9.84M invested in Evofem Biosciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

399% more call options, than puts

Call options by funds: $714K | Put options by funds: $143K

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

11% more capital invested

Capital invested by funds: $8.84M → $9.84M (+$1M)

10% more funds holding

Funds holding: 62 → 68 (+6)

18% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 17

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
14
Reduced
17
Closed
5
Calls
$714K
Puts
$143K
Net Calls
+$571K
Net Calls Change
-$107K

Top Buyers

Rank Fund Capital Flow
1
MCP
Mirador Capital Partners
California
+$1.14M
2
Citadel Advisors
Citadel Advisors
Florida
+$118K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$66.8K
4
Morgan Stanley
Morgan Stanley
New York
+$38K
5
TAM
Tocqueville Asset Management
New York
+$21.4K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.01M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$741K
3
GCP
GSA Capital Partners
United Kingdom
-$347K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$197K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$185K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$9K +$11K +1,750 New
Goldman Sachs
27
Goldman Sachs
New York
$8K -$13K -2,070 -56%
Commonwealth Equity Services
28
Commonwealth Equity Services
Massachusetts
$8K -$8.07K -1,283 -42%
CG
29
Cutler Group
California
$7K +$126 +20 +1%
Renaissance Technologies
30
Renaissance Technologies
New York
$6K -$51.1K -8,133 -87%
BSW
31
Buckingham Strategic Wealth
Missouri
$6K – – –
HF
32
HRT Financial
New York
$6K +$742 +118 +11%
TSS
33
Two Sigma Securities
New York
$6K +$7.52K +1,196 New
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$6K +$7.55K +1,200 +3,636%
SW
35
SteelPeak Wealth
California
$5K -$6.29K -1,000 -50%
PCS
36
Personal CFO Solutions
New Jersey
$5K – – –
PTP
37
Platform Technology Partners
New York
$4K – – –
Victory Capital Management
38
Victory Capital Management
Texas
$4K +$868 +138 +9%
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$4K +$4.2K +667 New
ARC
40
Advisor Resource Council
Texas
$3K – – –
GG
41
Gofen & Glossberg
Illinois
$3K – – –
JSW
42
Journey Strategic Wealth
New Jersey
$3K +$4.2K +667 New
WIM
43
Westside Investment Management
California
$2.97K – – –
Simplex Trading
44
Simplex Trading
Illinois
$2K – – –
IA
45
IFP Advisors
Florida
$2K +$13 +2 New
National Bank of Canada
46
National Bank of Canada
Quebec, Canada
$2K +$403 +64 +16%
UBS Group
47
UBS Group
Switzerland
$1K -$29.4K -4,674 -97%
Wells Fargo
48
Wells Fargo
California
$1K -$6 -1 -0.4%
HWA
49
HHM Wealth Advisors
Tennessee
$1K – – –
Northwestern Mutual Wealth Management
50
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
1
2
3

EVFM Hedge Fund Activity: Q1 2022 in Review

68 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2022, worth a combined $9.84M — up 11% from $8.84M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new EVFM positions and 5 closed out — a net gain of 6 holders — while 14 added to existing stakes and 17 trimmed.

The largest buyer was Mirador Capital Partners, adding an estimated $1.14M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.01M sold.

  • 68 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2022, up from 62 in Q4 2021.
  • Funds reported $9.84M of Evofem Biosciences, Inc. Common Stock stock for Q1 2022, up 11% quarter-over-quarter.
  • 11 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of +6 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2022 was Mirador Capital Partners, an estimated $1.14M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2022 was Baker Bros. Advisors, an estimated $1.01M sold.

Based on aggregated 13F filings for Q1 2022.